• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Retroperitoneal fibrosis in a patient with macroprolactinoma treated with bromocriptine.

作者信息

Herzog A, Minne H, Ziegler R

机构信息

Department of Internal Medicine I, Ruprecht-Karls-Universität, Heidelberg, West Germany.

出版信息

BMJ. 1989 May 13;298(6683):1315. doi: 10.1136/bmj.298.6683.1315-a.

DOI:10.1136/bmj.298.6683.1315-a
PMID:2500220
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1836500/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f4b/1836500/d9e91adf93c0/bmj00231-0059-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f4b/1836500/d9e91adf93c0/bmj00231-0059-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f4b/1836500/d9e91adf93c0/bmj00231-0059-a.jpg

相似文献

1
Retroperitoneal fibrosis in a patient with macroprolactinoma treated with bromocriptine.用溴隐亭治疗的大泌乳素瘤患者发生腹膜后纤维化。
BMJ. 1989 May 13;298(6683):1315. doi: 10.1136/bmj.298.6683.1315-a.
2
[Retroperitoneal fibrosis in a patient treated with bromocriptine for a prolactinoma].[一名因泌乳素瘤接受溴隐亭治疗的患者发生腹膜后纤维化]
J Urol (Paris). 1991;97(4-5):234-6.
3
Late development of resistance to bromocriptine in a patient with macroprolactinoma.一例大泌乳素瘤患者对溴隐亭耐药的晚期发生情况。
Horm Res. 1998;49(5):250-3. doi: 10.1159/000023180.
4
Cerebrospinal fluid (CSF) rhinorrhoea occurring six days after commencement of bromocriptine for invasive macroprolactinoma.溴隐亭用于侵袭性大泌乳素瘤治疗开始六天后出现脑脊液鼻漏。
Aust N Z J Med. 2000 Jun;30(3):399-400. doi: 10.1111/j.1445-5994.2000.tb00847.x.
5
CSF rhinorrhea after dopamine agonist treatment for invasive macroprolactinoma.多巴胺激动剂治疗侵袭性大泌乳素瘤后出现脑脊液鼻漏
Surg Neurol. 1990 Aug;34(2):133. doi: 10.1016/0090-3019(90)90111-2.
6
Notable effect of bromocriptine monotherapy on macroprolactinoma with self-limited cerebrospinal fluid rhinorrhea.溴隐亭单药治疗对伴有自限性脑脊液鼻漏的大泌乳素瘤有显著疗效。
Pol Arch Intern Med. 2019 Dec 23;129(12):927-929. doi: 10.20452/pamw.15095. Epub 2019 Dec 9.
7
Bromocriptine-induced schizophrenia.溴隐亭诱发的精神分裂症。
J Natl Med Assoc. 1993 Sep;85(9):700-1.
8
[Macroprolactinoma].[巨大泌乳素瘤]
Dtsch Med Wochenschr. 1996 Jul 26;121(30):962.
9
[Rhinorrhea and otorrhea: rare complications of the medical treatment in invasive prolactinomas].[鼻溢液和耳溢液：侵袭性催乳素瘤内科治疗的罕见并发症]
Ann Endocrinol (Paris). 1994;54(5):347-51.
10
Bromocriptine-induced cerebrospinal fluid fistula in patients with macroprolactinomas: report of three cases and a review of the literature.溴隐亭诱发大泌乳素瘤患者脑脊液瘘：三例报告及文献复习
Surg Neurol. 1994 Jun;41(6):486-9. doi: 10.1016/0090-3019(94)90013-2.

引用本文的文献

1
The Effect of Preoperative Cabergoline on Prolactinoma Fibrosis: A Case Series.术前卡麦角林对催乳素瘤纤维化的影响：病例系列
J Neurol Surg Rep. 2024 May 15;85(2):e66-e73. doi: 10.1055/s-0044-1786740. eCollection 2024 Apr.
2
Surgical Treatment of Prolactinomas: Potential Role as a First-Line Treatment Modality.泌乳素瘤的手术治疗：作为一线治疗方式的潜在作用。
Yonsei Med J. 2023 Aug;64(8):489-496. doi: 10.3349/ymj.2022.0406.
3
Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?

本文引用的文献

1
Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine.腹膜后纤维化与大剂量溴隐亭治疗帕金森病
Clin Neuropharmacol. 1986;9(2):200-1. doi: 10.1097/00002826-198604000-00012.
2
Pleuropulmonary and retroperitoneal fibrosis associated with bromocriptine treatment.与溴隐亭治疗相关的胸膜肺和腹膜后纤维化。
J Neurol Neurosurg Psychiatry. 1987 Dec;50(12):1706-7. doi: 10.1136/jnnp.50.12.1706.
3
Retroperitoneal fibrosis and bromocriptine.腹膜后纤维化与溴隐亭
多巴胺激动剂治疗泌乳素瘤：我们是否需要重新思考手术在泌乳素瘤管理中的地位？
Endocr Oncol. 2022 Apr 21;2(1):R31-R50. doi: 10.1530/EO-21-0038. eCollection 2022 Jan.
4
Classical dopamine agonists.经典多巴胺激动剂。
J Neural Transm (Vienna). 2019 Apr;126(4):449-454. doi: 10.1007/s00702-019-01989-y. Epub 2019 Feb 25.
Lancet. 1986 Aug 23;2(8504):466. doi: 10.1016/s0140-6736(86)92178-1.